With or without consolidation chemotherapy using cisplatin/5-FU after concurrent chemoradiotherapy in stage II-III squamous cell carcinoma of the esophagus: A propensity score-matched analysis
Background and purpose: The benefit of consolidation chemotherapy for locally advanced squamous cell carcinoma of the esophagus is unknown. The aim of this study was to investigate the efficacy of consolidation chemotherapy with cisplatin and 5-fluorouracil (5-FU) after concurrent chemoradiotherapy (CCRT) with the same agents in patients with stage II-III disease. Material and methods: Data for patients with stage II-III squamous cell carcinoma of the esophagus treated with CCRT were retroactively reviewed. Patients who received CCRT alone (observation group) were compared with those who underwent CCRT followed by consolidation chemotherapy (consolidation group) with regard to progression-free survival, overall survival, treatment failure and toxicity. Differences in baseline characteristics were adjusted using the propensity score matching method. Results: From September 2006 to September 2012, 812 patients were recruited (n = 272 for observation; n = 540 for consolidation). Among them, 290 (35.7%) had clinical stage II disease and 522 (64.3%) had stage III disease. In the overall study cohort, the median progression-free survival (22.1 months vs. 22.0 months, P = 0.917) and median overall survival (33.8 months vs. 31.3 months, P = 0.591) were comparable between the observation group and consolidation group. Comparisons of the observation and consolidation group in the matched population (262 patients in each group) showed median progression-free survival of 23.0 months and 25.4 months (hazard ratio [HR], 0.93; 95% CI [confidence interval], 0.74-1.15; P = 0.491), and median overall survival of 34.6 months and 35.0 months (HR, 0.92; 95% CI, 0.80-1.27; P = 0.919), respectively. There were no significant differences in local/regional failure and persistence disease (50.4% vs. 48.5%) and distant failure (10.7% vs. 8.8%) between the two groups. Conclusions: Compared to CCRT alone, consolidation chemotherapy did not further prolong progressionfree survival and overall survival for patients with stage II-III squamous cell carcinoma of the esophagus. The role of consolidation therapy needs to be studied further. (C) 2017 Elsevier B. V. All rights reserved. Radiotherapy and Oncology
基金：
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [U1604175]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院分区：
出版当年[2018]版：
大类|2 区医学
小类|2 区肿瘤学2 区核医学
最新[2025]版：
大类|2 区医学
小类|2 区肿瘤学2 区核医学
JCR分区：
出版当年[2018]版：
Q1RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGINGQ1ONCOLOGY
最新[2024]版：
Q1ONCOLOGYQ1RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
第一作者机构：[1]Wuhan Univ, Renmin Hosp, Dept Clin Oncol, Wuhan, Hubei, Peoples R China[2]Zhengzhou Univ, Dept Radiat Oncol, Affiliated Canc Hosp, Zhengzhou, Henan, Peoples R China
通讯作者：
通讯机构：[3]Hebei Med Univ, Hosp 4, Dept Radiat Oncol, Shijiazhuang, Hebei, Peoples R China[*1]Hebei Med Univ, Hosp 4, 12 Jiankang Rd, Shijiazhuang 050011, Hebei, Peoples R China
推荐引用方式(GB/T 7714)：
Chen Yongshun,Guo Liying,Cheng Xinyu,et al.With or without consolidation chemotherapy using cisplatin/5-FU after concurrent chemoradiotherapy in stage II-III squamous cell carcinoma of the esophagus: A propensity score-matched analysis[J].RADIOTHERAPY AND ONCOLOGY.2018,129(1):154-160.doi:10.1016/j.radonc.2017.10.031.
APA：
Chen, Yongshun,Guo, Liying,Cheng, Xinyu,Wang, Jun,Zhang, Yougai...&Shi, Wei.(2018).With or without consolidation chemotherapy using cisplatin/5-FU after concurrent chemoradiotherapy in stage II-III squamous cell carcinoma of the esophagus: A propensity score-matched analysis.RADIOTHERAPY AND ONCOLOGY,129,(1)
MLA：
Chen, Yongshun,et al."With or without consolidation chemotherapy using cisplatin/5-FU after concurrent chemoradiotherapy in stage II-III squamous cell carcinoma of the esophagus: A propensity score-matched analysis".RADIOTHERAPY AND ONCOLOGY 129..1(2018):154-160
医学